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A B S T R A C T
Dipeptidyl peptidase 4 (DPP‑4) inhibitors represent a new pharmacological class of 
glucose – lowering agents, mainly used as add‑on therapy, after metformin or combi‑
nation of metformin with sulfonylurea or metformin with a thiazolidinedione. Over 
the last few years, several DPP‑4 inhibitors, also called gliptins, have been approved 
and introduced into clinical practice such as sitagliptin, linagliptin, saxagliptin, vilda‑
gliptin and alogliptin. Their mechanism of action relates to the inhibition of the DPP‑
4 enzyme which degrades the incretin hormones, e.g. glucagon‑like peptide‑1 (GLP‑1) 
and glucose‑dependent insulinotropic polypeptide (GIP), released from the small in‑
testine into the circulation during a meal, potentially capable to stimulate the release 
of insulin from pancreatic beta cells, thus affording a glucose‑lowering action. How‑
ever, these incretins are swiftly degraded by the DPP‑4 enzyme. Gliptins, therefore, 
inhibit this enzyme, enhancing the bioavailability of GLP‑1 and GIP. They have been 
approved for better glycemic control in type 2 diabetic patients.
Although, these new agents have been heralded as safe agents conferring pleiotropic 
or cardioprotective effects, recent studies showed that the new DPP‑4 inhibitors may 
not have serious adverse cardiovascular effects, but have failed to show any pleiotropic 
actions or favorable cardiovascular effects. Additional data from ongoing studies may 
shed further light on this issue.
I N T R O D U C T I O N
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disease associated with an 
increased rate of mortality and morbidity, mainly due to microvascular and macrovas‑
cular disease.1 Adequate glycemic control with classical drugs, such as metformin, sul‑
fonylurea derivatives, and insulin all can improve glycemic control and reduce, mainly, 
the microvascular complications. However, these therapies have not shown a similar 
improvement in the reduction of macrovascular complications, including coronary heart 
disease (CHD) and peripheral artery disease (PAD).2 Moreover, the available data 
from large clinical trials have shown controversial effects of the tight glycemic control 
concerning the reduction of all‑cause mortality in patients with T2DM.3 All the above 
therapies have shown no significant reduction of cardiovascular risk beyond glycemic 
control and additionally thiazolidinediones have been associated with an increased 
risk of cardiovascular mortality.4
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AbbreviAtions
ACE = angiotensin converting enzyme 
CHD = coronary heart disease 
CV = cardiovascular
DPP‑4 = dipeptidyl peptidase 4 
G‑CSF = granulocyte colony‑stimulating 
factor 
GIP = insulinotropic polypeptide 
GLP‑1 = glucagon‑like peptide‑1 
MACE = major adverse cardiovascular 
events 
MI = myocardial infarction
SDF1α = stromal cell-derived factor 1α 
T2DM = type 2 diabetes mellitus
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Dipeptidyl peptidase 4 (DPP‑4) inhibitors represent a 
newly introduced pharmacological class of glucose – lowering 
agents predominantly used as second‑ or third‑line agents, typi‑
cally after metformin or the combination of metformin – sul‑
fonylurea or metformin – thiazolidinedione. Their mechanism 
of action relates to the inhibition of the DPP‑4 enzyme which 
degrades incretins. Two of the most recognized gut‑secreted 
incretins are the glucagon‑like peptide‑1 (GLP‑1), which is 
a specific ligand for the G protein‑coupled GLP‑1 receptor 
(GLP‑1R) and the glucose‑dependent insulinotropic polypep‑
tide (GIP), which control the postprandial glucose‑dependent 
stimulation of insulin secretion by pancreas.5,6 The activity of 
GIP in patients with T2DM is lost whereas that of GLP‑1 is 
weak.7 Although the administration of GLP‑1 analogues has 
been shown to have a positive effect on plasma glucose regula‑
tion, the final therapeutic result is limited mainly due to the 
degradation activity of the DPP‑4 enzyme. Over the last few 
years, several DPP‑4 inhibitors, also called gliptins, have been 
approved and introduced into clinical practice such as sitaglip‑
tin, linagliptin, saxagliptin, vildagliptin and alogliptin. These 
compounds result in a mean decrease in glycated hemoglobin 
(HbA1C) ranging between 0.5% and 1% having additionally 
a minor risk of hypoglycemia and body weight gain. Further‑
more, clinical studies have shown that gliptins increase the 
concentration of other peptides with cardioprotective effects 
independently of their action on the GLP‑1 receptors, which 
are also located on the cardiovascular system (Fig. 1).8 This 
review will focus on the potential effects of the DPP‑4 inhibi‑
tors on the cardiovascular system.
I M P A C T  O F  D P P - 4  I N H I B I T O R S  O N 
C A R D I O V A S C U L A R  R I S K  F A C T O R S
Many antidiabetic drugs have been shown to have ben‑
eficial effects on diabetic dyslipidemia, in both fasting and 
postprandial state.9 Experimental studies with either GLP‑1 
receptor agonists or DPP‑4 inhibitors have indicated that 
GLP‑1 could have an inhibitory effect on the intestinal pro‑
duction of triglyceride‑rich lipoproteins independently of 
weight changes.10 Therapy with vildagliptin has been shown to 
improve the postprandial triglyceride and apolipoprotein B‑48 
particle metabolism.11 This enhancement of postprandial lipid 
mobilization and oxidation seems to be caused by an increase 
in postprandial adipose tissue lipolysis via activation of the 
sympathetic nervous system rather than via a direct effect on 
metabolic status.12 A retrospective analysis based on the Gen‑
eral Electric Centricity database from 1996 to 2008, included 
5,861 patients who were treated with the DPP‑4 inhibitor 
sitagliptin. These patients showed decreases in low‑density 
lipoprotein cholesterol, total cholesterol, and triglycerides.13 
Moreover, the results from a metaanalysis showed that patients 
under DPP‑4 inhibitor treatment had a significant difference 
in total cholesterol compared to controls before and after 
treatment.14 
With regards to hypertension, which commonly coexists 
in patients with T2DM, DPP‑4 inhibitors may decrease the 
blood pressure either directly through DPP‑4 inhibition or 
via the modulation of incretin hormone physiology. A small 
study, which enrolled non diabetic patients with mild to mod‑
erate hypertension, showed that sitagliptin produced slightly 
statistically significant reductions of 2–3 mmHg systolic and 
1.6–1.8 mmHg diastolic blood pressure as assessed by 24‑hour 
ambulatory blood pressure monitoring.15 The favorable effect 
of sitagliptin on blood pressure seems to be reversed when a 
high dose of angiotensin‑converting‑enzyme inhibitor (ACE‑I) 
is co‑administrated. Marney et al16 suggested that high levels 
of substance P and decreased degradation of neuropeptide Y, 
because of the double blockade of ACE (enalapril 10 mg) and 
DPP‑4 (sitagliptin), caused the activation of the sympathetic 
nervous system eliminating thus the vasodilatory effects. Ad‑
ditional data support a dose‑dependent reduction in blood 
FIgURE 1. Pleiotropic effects of DPP‑4 inhibitors on cardiovascular risk factors. DPP‑4 = dipeptidyl peptidase 4.
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pressure since patients receiving 100 mg vildagliptin vs 50 mg 
vildagliptin had significantly greater reduction in diastolic 
blood pressure compared to placebo.17 The novel mechanisms 
underlying the effects of DPP4 inhibitors on lipid metabolism, 
fasting and postprandial, remain to be explored through more 
extensive prospective clinical studies.
E F F E C T  O F  D P P - 4  I N H I B I T O R S  
O N  P R O C E S S  O F  A T H E R O S C L E R O S I S 
A N D  C O R O N A R y  H E A R T  D I S E A S E
E N D O T H E L I A L  D y S F U N C T I O N  
A N D  I N F L A M M A T I O N  P R O C E S S
It is well known that endothelial dysfunction is common 
in T2DM and is considered an independent cardiovascular 
risk factor. Increasing evidence exists that GLP‑1 analogues 
administration might ameliorate endothelial dysfunction in 
patients with T2DM reducing the coronary heart disease 
risk.18 Experimental data in mice show that DPP‑4 inhibitors 
reduce inflammation via inhibition of monocyte activation 
and chemotaxis.19 Furthermore, data from patients with 
T2DM receiving sitagliptin show an increase in the levels of 
circulating vasculoprotective endothelial progenitor cells and 
a concomitant upregulation of stromal cell-derived factor 1α 
(SDF1α), which is a substrate of DPP4.20 Diabetic patients 
who were receiving vildagliptin for one month, had a better 
endothelium‑dependent vasodilatation compared to acarbose 
therapy.21 Moreover, after six months of therapy with sitaglip‑
tin, a significant reduction of microalbuminuria was reported 
in patients with T2DM, which is considered a specific marker 
of endothelial dysfunction.22
C O R O N A R y  H E A R T  D I S E A S E  ( C H D )
Although data from human studies concerning the impact 
of DDP‑4 inhibitors on ischemic heart disease is limited, there 
is evidence from small studies that these drugs have a beneficial 
protective anti‑ischemic effect independently of their hypo‑
glycemic action. Read et al studied the effect of sitagliptin on 
left ventricular function in patients suffering from CHD who 
underwent dobutamine stress echocardiography, based on the 
hypothesis that increasing the plasma concentration of GLP‑1 
by DPP‑4 inhibition would protect the heart from ischemic left 
ventricular dysfunction. At peak stress and during the phase 
of recovery, researchers observed that the increase of plasma 
levels of GLP‑1 was accompanied by an enhancement on left 
ventricular response to stress, both globally and regionally in 
the 12 paired non‑apical segments as assessed by peak systolic 
tissue Doppler. In the recovery phase, sitagliptin attenuated 
the post ischemic stunning seen after the control study.23
After myocardial infarction DPP‑4 inhibition can reduce 
the size of the infarct and reverse left ventricular remodeling.24 
A trial studied 100 patients with acute myocardial infarction 
after successful percutaneous coronary intervention who were 
randomized to placebo or granulocyte colony‑stimulating 
factor (G‑CSF) for 5 days plus sitagliptin for 28 days. The 
objective was to examine the effects of the combination of 
G‑CSF plus sitagliptin on myocardial regeneration process 
by studying the improved myocardial homing of the mobilized 
stem cells. The process of myocardial stem cell homing involves 
the interaction of SDF-1α, which is cleaved by the enzyme 
DPP‑4, and the cellular homing receptor C–X–C chemokine 
receptor type 4. Preliminary results confirm that a high level 
of cellular DPP‑4 expression after myocardial infarction de‑
creases the migration of peripheral blood mononuclear cells 
towards SDF-1α, and negatively influences cardiac function 
after a myocardial infarction.25 Sitagliptin has also been shown 
to have an inhibitory effect on the platelet aggregation in 
both healthy individuals and diabetic patients. This seems 
to be caused primarily via the inhibitory effect of sitagliptin 
on intracellular free calcium and tyrosine phosphorylation.26
C U R R E N T  E V I D E N C E  F O R 
C A R D I O V A S C U L A R  O U T C O M E S  
A N D  S A F E T y
A recent study assessed the cardiovascular safety of 
sitagliptin in patients with T2DM from 25 double‑blind stud‑
ies, which randomized patients at baseline to sitagliptin or a 
non‑sitagliptin comparator. The main objective was to assess 
the major adverse cardiovascular events (MACE) including 
ischemic event and cardiovascular death rates. Analysis of 
the results showed that 40 patients in the sitagliptin group 
and 38 in the non‑sitagliptin group had at least one reported 
MACE‑related event. In this analysis, the exposure adjusted 
incidence rate was 0.65 per 100 patient‑years in the sitagliptin 
group and 0.74 in the non‑sitagliptin group. Therefore, this 
pooled analysis did not indicate that treatment with sitagliptin 
increases cardiovascular risk in patients with T2DM.27 Simi‑
larly, a meta‑analysis of 53 randomized clinical trials reported 
that DPP‑4 inhibitors had a similar risk of MACE, cancer or 
pancreatitis compared with placebo or other treatment.28 The 
safety of vildagliptin was assessed regarding cardiovascular and 
cerebrovascular events. Categories included in the composite 
endpoint were acute coronary syndrome, transient ischemic 
attack with imaging evidence of infarction, stroke, and cer‑
ebrovascular death. The risk ratios (RR) for the composite 
endpoint were <1 for both vildagliptin 50 mg qd and vildaglip‑
tin 50 mg bid. These results were consistent across subgroups 
defined by age, gender, and cardiovascular risk status. The 
investigators concluded that vildagliptin was not associated 
with an increased risk of adjudicated cerebrovascular events 
relative to all comparators in the broad population of T2DM 
including patients at increased risk of cerebrovascular events.29
Recently, results were presented and published from two 
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major cardiovascular (CV) outcomes trials, EXAMINE and 
SAVOR‑TIMI 53 Trials,30‑32 showing that the new DPP‑4 
inhibitors, saxagliptin and alogliptin, may not have serious 
adverse CV effects, but failed to show any pleiotropic actions 
or favorable CV effects.33 In the EXAMINE study,31 a total of 
5380 patients with T2DM and either an acute MI or unstable 
angina within the previous 15‑90 days underwent randomiza‑
tion to alogliptin or placebo and were followed for up to 40 
months (median, 18 months). A primary end‑point event 
(CV death, MI or stroke) occurred in 305 patients assigned 
to alogliptin (11.3%) and in 316 patients assigned to placebo 
(11.8%) (hazard ratio‑HR, 0.96). Glycated hemoglobin lev‑
els were significantly lower with alogliptin than with placebo 
(mean difference, −0.36 percentage points; P<0.001). Inci‑
dences of hypoglycemia, cancer, pancreatitis, and initiation 
of dialysis were similar with alogliptin and placebo.
In the SAVOR‑TIMI 53 study,32 16,492 patients with 
T2DM with history of, or at risk for, CV events were randomly 
assigned to receive saxagliptin or placebo. At 2 years, a pri‑
mary end‑point event (CV death, myocardial infarction‑MI, 
or ischemic stroke) occurred in 613 patients (7.3%) in the 
saxagliptin group and in 609 patients in the placebo group 
(7.2%) (P=NS). The major secondary end point (CV death, 
MI, stroke, hospitalization for unstable angina, coronary 
revascularization, or heart failure) occurred in 1059 patients 
(12.8%) in the saxagliptin group and in 1034 patients in 
the placebo group (12.4%) (P=NS). More patients in the 
saxagliptin group (3.5%) than in the placebo group (2.8%) 
were hospitalized for heart failure (hazard ratio‑HR, 1.27; 
P=0.007). Rates of pancreatitis were similar in the two groups 
(acute pancreatitis, 0.3% in the saxagliptin group and 0.2% in 
the placebo group; chronic pancreatitis, <0.1% and 0.1% in 
the two groups, respectively). 
At present, the safety and any potential cardioprotective 
effects of DPP‑4 inhibitors are being tested further in ongoing 
multicenter clinical trials, whereby the primary MACE end‑
point considered is a cardiovascular safety outcome to reduce 
the risk of events. TECOS (Randomized, Placebo‑Controlled 
Clinical Trial to Evaluate Cardiovascular Outcomes after 
Treatment with Sitagliptin in Patients With T2DM and In‑
adequate Glycemic Control) is a phase III non‑inferiority 
trial designed to assess cardiovascular outcomes of long‑term 
treatment with sitagliptin in patients with T2DM (HbA1c of 
6.5–8.0%) and a history of cardiovascular disease. Finally, 
CAROLINA (Cardiovascular Outcome Study of Linagliptin 
versus Glimepiride in Patients with T2DM) is a multicenter 
study planning to enroll about 6,000.34
C O N C L U S I O N
All the above data demonstrate that DPP‑4 inhibitors are 
promising antidiabetic drugs with potential pleiotropic effects 
on the cardiovascular system. Beyond their hypoglycemic ac‑
tion, they may improve the lipid profile and the endothelial 
dysfunction decreasing the inflammatory response, and re‑
ducing myocardial injury. However, although safety of these 
agents seems to have been documented by recent trials, the 
alleged cardioprotective effects of DPP‑4 inhibition have not 
been confirmed by initial cardiovascular outcomes studies. 
According to the regulatory requirements and for the cardio‑
vascular safety of all new anti‑diabetic drugs, more clinical 
trials involving different DPP‑4 inhibitors and cardiovascular 
outcomes are currently underway. These trials do not allow 
direct comparison between specific agents, but they may 
provide new data regarding the exact mechanisms of cardio‑
vascular effects of DPP‑4 inhibitors. Finally, gliptins do not 
seem to increase the cardiovascular risk, nor do they appear to 
reduce it, thus leading us to seek other approaches to reduce 
this risk, refocusing back at conventional risk factors, such as 
control of hyperlipidemia, hypertension, smoking, and obesity, 
rather than relying on glycemic control as a proxy of reduced 
cardiovascular risk.34 
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